12 Farnesyl Transferase Inhibitor (FTI) Darlifarnib Combined with Cabozantinib in Renal Cell Carcinoma (RCC): Updated Phase 1a Results from FIT-001
Abstract Background VEGFR- and IO-targeted therapies for metastatic RCC have limitations that can lead to disease progression, highlighting the need for well-tolerated and effective combination strategies. VEGFR-TKI resistance occurs through multiple escape mechanisms, with the mTOR pathway playing a central role in su...